2 Healthcare Stocks to Buy Before They Get Bought Out
2026-03-20 05:54:00 ET
Abivax (NASDAQ: ABVX) and Nektar Therapeutics (NASDAQ: NKTR) aren't well-known companies, and they don't have track records of profitability yet. That's natural, as both are clinical-stage biotechs -- they don't have any approved drugs on the market yet. However, both are developing novel therapies with blockbuster potential, and both could be worthwhile stocks to own.
Abivax is down by around 10% this year, while Nektar is up by about 77%. Here are three reasons to consider buying each stock.
French biotech Abivax is developing therapies for chronic inflammatory diseases. Its lead candidate is obefazimod, which is being tested to treat ulcerative colitis, Crohn's disease, and other conditions.
NASDAQ: ABVX
ABVX Trading
2.74% G/L:
$125.59 Last:
545,893 Volume:
$123.99 Open:
